Analyst Reco. Allakos Inc.

Equities

ALLK

US01671P1003

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
1 ^USD	-5.66%		-9.91%	-63.37%

25/06	Allakos Reports 'Positive' Results From Phase 1 Trial of Antibody That Inhibits Mast Cells	MT
25/06	Allakos Inc. Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JMP Securities Adjusts Allakos' Price Target to $3 From $10, Maintains Market Outperform Rating	17/01	MT
Barclays Trims Allakos' Price Target to $1 From $1.50, Maintains Underweight Rating	17/01	MT
Jefferies Downgrades Allakos to Hold From Buy, Adjusts Price Target to $1.50 From $6	17/01	MT
Cantor Fitzgerald Downgrades Allakos to Neutral From Overweight	17/01	MT
Lifesci Capital Downgrades Allakos to Market Perform From Outperform	17/01	MT
William Blair Upgrades Allakos to Outperform From Market Perform	18/12	MT
JMP Securities Adjusts Price Target on Allakos to $10 From $11, Maintains Market Outperform Rating	14/11	MT
Barclays Adjusts Price Target on Allakos to $1.50 From $2.50, Maintains Underweight Rating	14/11	MT
JMP Securities Initiates Allakos With Outperform Rating, Price Target is $11	27/23/27	MT
Jefferies Upgrades Allakos to Buy From Hold, Raises Price Target to $9 From $6	12/23/12	MT
Piper Sandler Starts Allakos at Overweight With $22 Price Target	07/23/07	MT
SMBC Nikko Downgrades Allakos to Underperform From Neutral, Lowers Price Target to $2 From $4	12/22/12	MT
Cantor Fitzgerald Trims Price Target on Allakos to $7 From $10, Maintains Overweight Rating	12/22/12	MT
Goldman Sachs Adjusts Allakos' Price Target to $4 from $10, Keeps Neutral Rating	24/22/24	MT
Barclays Adjusts Allakos' Price Target to $2.50 from $7, Keeps Underweight Rating	11/22/11	MT
Morgan Stanley Adjusts Price Target for Allakos to $6 From $8, Maintains Equalweight Rating	09/22/09	MT
Barclays Adjusts Allakos' Price Target to $7 From $8, Reiterates Underweight Rating	16/22/16	MT
Goldman Sachs Adjusts Allakos' Price Target to $11 From $60, Maintains Neutral Rating	16/22/16	MT
SVB Leerink Adjusts Allakos' Price Target to $13 from $17, Maintains Market Perform Rating	16/22/16	MT
Morgan Stanley Adjusts Allakos Price Target to $8 From $10, Reiterates Equalweight Rating	01/22/01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Allakos Inc.

Equities

ALLK

US01671P1003

Analyst Reco.

Filters